Halliburton stock extends pullback after profit tops expectations but revenue comes up shy
Shares of Halliburton Co. (HAL) slipped 0.4% toward a three-day losing streak in premarket trading Tuesday, after the oil services company topped third-quarter profit expectations but came up a bit short on revenue, amid weakness in North America. Net income rose to $716 million, or 79 cents a share, from $544 million, or 60 cents a share, in the year-ago period. The FactSet consensus for earnings per share was 77 cents. Revenue grew 8.3% to $5.804 billion, below the FactSet consensus of $5.848 billion. North America revenue fell 1% to $2.608 billion, while international revenue jumped 17.4% to $3.196 billion. "I am pleased with the stability of our North America business and the profitability of our international growth," said Chief Executive Jeff Miller. "Everything I see today strengthens my conviction in the long duration of this upcycle. Against this backdrop, we expect continued demand growth for oilfield services in 2024 and beyond." The stock has pulled back 3.7% over the past two sessions after closing Oct. 19 at $43.26, the highest close since July 2018. It has rallied 8.9% over the past three months through Monday while the S&P 500 has shed 7.4%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-24-23 0659ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth